Hemolytic Anemias

Hemolytic anemias are a diverse group of disorders characterized by the premature destruction of red blood cells, leading to anemia and compensatory bone marrow response. These conditions may be inherited or acquired and result from intrinsic red cell defects or extrinsic factors such as immune mechanisms, infections, or mechanical injury. Clinical manifestations include fatigue, jaundice, dark urine, splenomegaly, and, in severe cases, hemolytic crises. Laboratory findings typically demonstrate elevated lactate dehydrogenase, indirect bilirubin, reticulocytosis, and reduced haptoglobin levels. Accurate classification of hemolytic anemia is essential for effective management and relies on detailed clinical assessment and specialized tests. Treatment strategies vary widely, ranging from supportive care and transfusion therapy to immunosuppression or splenectomy in selected cases. Recent advances in molecular diagnostics and immunology have enhanced understanding of disease mechanisms, enabling more precise and individualized therapeutic approaches. Hemolytic anemias remain a significant focus of research due to their complexity and potential for life-threatening complications.